Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cyclacel Pharmaceuticals

13.07
+4.8458.81%
Post-market: 12.13-0.9400-7.19%19:59 EDT
Volume:22.37M
Turnover:330.85M
Market Cap:20.70M
PE:-0.03
High:18.00
Open:8.00
Low:8.00
Close:8.23
Loading ...

Cyclacel Pharmaceuticals trading halted, volatility trading pause

TIPRANKS
·
18 Jul

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

GlobeNewswire
·
16 Jul

Cyclacel Pharmaceuticals Secures $3 Million in Series F Preferred Stock Sale

Reuters
·
08 Jul

Cyclacel announces amendment to exchange agreement with Fitters

TIPRANKS
·
07 Jul

Cyclacel Pharmaceuticals Announces Amendment to Exchange Agreement

THOMSON REUTERS
·
07 Jul

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

GlobeNewswire
·
07 Jul

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

GlobeNewswire
·
07 Jul

Cyclacel Pharmaceuticals trading halted, news pending

TIPRANKS
·
04 Jul

Cyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split Effective July 7, 2025

Reuters
·
02 Jul

Cyclacel Pharmaceuticals Announces Stock Split

THOMSON REUTERS
·
02 Jul

Cyclacel Pharmaceuticals Inc. Concluded Annual Shareholder Meeting

Reuters
·
01 Jul

Cyclacel Pharmaceuticals Secures $3 Million Through Preferred Stock Agreement with Investors

Reuters
·
26 Jun

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

THOMSON REUTERS
·
21 Jun

Press Release: Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Dow Jones
·
21 Jun

Cyclacel Pharmaceuticals Inc. Declares Quarterly Cash Dividend of $0.15 Per Share on Preferred Stock

Reuters
·
04 Jun

Cyclacel Pharmaceuticals Regains Nasdaq Compliance After Meeting Minimum Bid Price Requirement

Reuters
·
04 Jun

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
04 Jun

Cyclacel Pharmaceuticals Approves Reverse Stock Split Amendment

Reuters
·
24 May

Cyclacel Pharmaceuticals Reports First Quarter Results: General and Administrative Expenses Rise by $2.6 Million, Plogosertib Focused Development Continues

Reuters
·
16 May

Cyclacel Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement; Ho Kee Wee Named as 10% Owner

Reuters
·
16 May